Zytiga fallout: Stringent EU HTAs mean Dendreon may need 65-70% off Provenge
This article was originally published in Scrip
Executive Summary
The European prostate cancer treatment space is characterized by economic austerity and strict reimbursement regulation. Nevertheless, Dendreon is preparing to launch Provenge in Europe in an attempt to counter the vaccine's disappointing US launch in April 2010. European health technology assessors have already blocked drugs which are more convenient and bear costs approximately one-third those of Provenge in the US. Adding those specific hurdles to the general economic environment for cancer drugs in Europe makes it likely that Dendreon will have to look for revenue growth elsewhere.